
Acasti Pharma ACST
Quarterly report 2025-Q4
added 02-12-2026
Acasti Pharma Total Shareholders Equity 2011-2026 | ACST
Annual Total Shareholders Equity Acasti Pharma
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 66.6 M | 61.7 M | 68 M | 108 M | 55.7 M | 13 M | 11 M | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 108 M | 11 M | 54.9 M |
Quarterly Total Shareholders Equity Acasti Pharma
| 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 64.9 M | 62.8 M | 63.6 M | 66.6 M | 52.1 M | 56.1 M | 59.4 M | 61.7 M | 64.7 M | 66.7 M | 64 M | 68 M | 96.7 M | 100 M | 104 M | 108 M | 111 M | 114 M | 53.5 M | 55.7 M | 25.7 M | 25.7 M | 8.87 M | 11 M | -4.29 M | -759 K | 3.28 M | 11 M | - | - | - | 7.19 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 114 M | -4.29 M | 54.6 M |
Total Shareholders Equity of other stocks in the Biotechnology industry
| Issuer | Total Shareholders Equity | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
621 M | - | 2.43 % | $ 254 M | ||
|
Xeris Pharmaceuticals
XERS
|
13.7 M | $ 6.03 | -1.55 % | $ 885 M | ||
|
I-Mab
IMAB
|
1.72 B | - | - | $ 866 M | ||
|
UroGen Pharma Ltd.
URGN
|
-105 M | $ 19.2 | -11.52 % | $ 554 M | ||
|
uniQure N.V.
QURE
|
199 M | $ 10.89 | -30.36 % | $ 530 M | ||
|
GT Biopharma
GTBP
|
5.79 M | $ 0.47 | -2.41 % | $ 892 K | ||
|
Biophytis SA
BPTS
|
2.27 M | - | -13.47 % | $ 169 M | ||
|
AbCellera Biologics
ABCL
|
967 M | $ 3.74 | 3.6 % | $ 1.12 B | ||
|
Midatech Pharma plc
MTP
|
6.72 M | - | -18.52 % | $ 27.3 M | ||
|
Adverum Biotechnologies
ADVM
|
70.7 M | - | - | $ 86.2 M | ||
|
ARCA biopharma
ABIO
|
382 M | - | 1052.0 % | $ 415 M | ||
|
Acer Therapeutics
ACER
|
-16.8 M | - | 2.71 % | $ 14 M | ||
|
Alpine Immune Sciences
ALPN
|
179 M | - | - | $ 2.17 B | ||
|
Acorda Therapeutics
ACOR
|
-158 M | - | -24.86 % | $ 820 K | ||
|
CureVac N.V.
CVAC
|
688 M | - | - | $ 867 M | ||
|
AgeX Therapeutics
AGE
|
5.47 M | - | -10.17 % | $ 12.2 K | ||
|
Aeglea BioTherapeutics
AGLE
|
715 M | - | - | $ 1.01 B | ||
|
Applied Genetic Technologies Corporation
AGTC
|
29.5 M | - | - | $ 26.5 M | ||
|
AIkido Pharma
AIKI
|
39.9 M | - | 1.93 % | $ 17.4 M | ||
|
Agenus
AGEN
|
-160 M | $ 3.36 | 0.86 % | $ 1.2 M | ||
|
Ayala Pharmaceuticals
AYLA
|
-1.1 M | - | - | $ 7.46 M | ||
|
Akero Therapeutics
AKRO
|
750 M | - | - | $ 3.67 B | ||
|
Agios Pharmaceuticals
AGIO
|
1.19 B | $ 29.16 | -3.54 % | $ 1.69 B | ||
|
Advaxis
ADXS
|
-24.4 M | - | -9.65 % | $ 45.9 M | ||
|
Akouos
AKUS
|
234 M | - | 0.23 % | $ 488 M | ||
|
Albireo Pharma
ALBO
|
176 M | - | -0.23 % | $ 916 M | ||
|
Alector
ALEC
|
30.6 M | $ 2.19 | -9.77 % | $ 226 M | ||
|
Entera Bio Ltd.
ENTX
|
6.66 M | $ 1.38 | -0.72 % | $ 63.3 M | ||
|
Allena Pharmaceuticals
ALNA
|
18.9 M | - | 3.16 % | $ 1.9 M | ||
|
Aileron Therapeutics
ALRN
|
54.4 M | - | 10.36 % | $ 9.8 M | ||
|
Altimmune
ALT
|
124 M | $ 4.21 | -2.32 % | $ 299 M | ||
|
AlloVir
ALVR
|
113 M | - | 4.14 % | $ 49.1 M | ||
|
Evogene Ltd.
EVGN
|
56.9 M | $ 0.84 | -4.24 % | $ 27.9 M | ||
|
Ampio Pharmaceuticals
AMPE
|
3.36 M | - | -11.43 % | $ 502 K | ||
|
Amarin Corporation plc
AMRN
|
459 M | $ 13.98 | 1.27 % | $ 5.7 B | ||
|
AbbVie
ABBV
|
-3.27 B | $ 233.57 | 0.64 % | $ 413 B | ||
|
Blueprint Medicines Corporation
BPMC
|
299 M | - | - | $ 8.14 B | ||
|
Applied Molecular Transport
AMTI
|
60.8 M | - | - | $ 10.1 M | ||
|
AIM ImmunoTech
AIM
|
38.5 M | $ 0.8 | -11.6 % | $ 38.5 M | ||
|
Aptorum Group Limited
APM
|
21.1 M | $ 0.83 | 5.37 % | $ 4.53 M | ||
|
Apellis Pharmaceuticals
APLS
|
370 M | $ 20.67 | -1.38 % | $ 2.61 B |